Cancer treatments in phase 3 trials successful up to half of the time

Cancer remains the second leading cause of death in the United States, but continuous improvements have been made in survival and other outcomes, according to background information in the article.

“To a large extent, this has occurred through the introduction of new treatments tested in clinical trials, with randomized controlled trials (RCTs) widely considered to be the most reliable method of assessing differences between the effects of health care interventions,” the authors write. “Cancer is the only disease for which the National Institutes of Health has consistently funded a cooperative clinical trial infrastructure. Despite this investment, little is known about the proportion of clinical trials that have led to the discovery of successful new treatments.”

Benjamin Djulbegovic, M.D., Ph.D., of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, and colleagues extracted data from all completed phase 3 randomized clinical trials conducted by the National Cancer Institute cooperative groups since their inception in 1955. A total of 624 trials involving 216,451 patients were analyzed.

Overall, 30 percent of the trials had statistically significant results; in 80 percent of those cases, new treatments were superior to established protocols. The original researchers reported that the risk-benefit ratio favored new treatments in 41 percent of comparisons, while standard treatments were favored in 59 percent of comparisons.

“The real effects of new treatments compared with standard treatments in terms of patient outcomes such as survival is best measured by quantitative pooling of data,” the authors write. “When done this way, new treatments are, on average, found to be slightly superior to standard treatments, with a 5 percent relative reduction in the death rate. This, of course, should not be understood as the average effects of new discoveries being equally spread among all patients.” In 15 percent of the trials, breakthrough therapies were discovered; in 2 percent of the cases, these reduced the death rate by more than 50 percent.

Source: JAMA and Archives Journals

Cell's 'power plant' genes raise vision disorder risk
Genetic variation in the DNA of mitochondria – the “power plants” of cells – contributes to a person’s risk of developing age-related macular degeneration (AMD), Vanderbilt investigators report May 7 in the journal PLoS ONE.
Spinal cord injury research hampered by animal models, says new study
Research on traumatic spinal cord injuries is hampered by a reliance on animal experiments that don’t accurately predict human outcomes, says a new study in the upcoming edition of the peer-reviewed journal Reviews in the Neurosciences. The review was written by scientists with the Physicians Committee for Responsible Medicine.
Clinical symptoms just as good as lab trials for AIDS patients: WHO
AIDS sufferers whose treatment is assessed by simple clinical signs are almost on a par with those whose therapies are based on advanced laboratory analysis, the World Health Organisation said Friday.
Autistic mannerisms reduced by sensory treatment
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they’re seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
Rat study suggests why teens get hooked on cocaine more easily than adults
New drug research suggests that teens may get addicted and relapse more easily than adults because developing brains are more powerfully motivated by drug-related cues. This conclusion has been reached by researchers who found that adolescent rats given cocaine – a powerfully addicting stimulant – were more likely than adults to prefer the place where they got it. That learned association endured: Even after experimenters extinguished the drug-linked preference, a small reinstating dose of cocaine appeared to rekindle that preference – but only in the adolescent rats.
Survey offers first-ever look at treatment practices for nonepileptic seizures
A new nationwide clinician survey provides the first comprehensive look at what is community care or ‘treatment as usual’ for nonepileptic seizures (NES), laying the groundwork for clinical trials aimed at identifying effective treatments for this neuropsychiatric disorder.
Report describes first targeted therapy to produce remission of metastatic melanoma
In a demonstration that even some of the most hard-to-treat tumors may one day succumb to therapies aimed at molecular "weak points," researchers at Dana-Farber Cancer Institute report the first instance in which metastatic melanoma has been driven into remission by a targeted therapy.
Studies don't support common treatments for patchy hair loss
If clumps of your hair start to fall out from a common form of baldness, a new review of existing research unfortunately offers little comfort.

Cancer treatments in phase 3 trials successful up to half of the time

Related stories:

News discussion: